Enoxacin
ANTIINFECTIVES FOR SYSTEMIC USE
Also known as: enofloxacin, enofloxacine, enoksetin, enoxacine
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Enoxacin is an ofm drug catalogued in DrugCentral. It was first approved by the FDA in 1991. DrugCentral lists 5 molecular targets, including TARBP2, ATP6V1B2 and gyrA. Recorded indications include Acute gonococcal cervicitis, Acute gonococcal urethritis, Gonorrhea and Gonorrhea of pharynx.
- Approval status: ofm (first approved 1991 by the FDA).
- Molecular targets: TARBP2, ATP6V1B2, gyrA and parC|topB (5 listed in DrugCentral).
- Indications: Acute gonococcal cervicitis, Acute gonococcal urethritis, Gonorrhea, Gonorrhea of pharynx and Gonorrhea of rectum and others.
- ATC code: J01MA04 (Fluoroquinolones).
- Molecular formula: C15H17FN4O3; molecular weight 320.32 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (6)
- Acute gonococcal cervicitis
- Acute gonococcal urethritis
- Gonorrhea
- Gonorrhea of pharynx
- Gonorrhea of rectum
- Urinary tract infectious disease
Off-label uses (1)
- Chancroid
Mechanism & targets
Molecular targets (5)
| Target | Gene | Action | Activity |
|---|---|---|---|
| RISC-loading complex subunit TARBP2 | TARBP2 | unknown | Kd 7.03 |
| V-type proton ATPase subunit B, brain isoform | ATP6V1B2 | unknown | IC50 5.00 |
| DNA gyrase subunit A | gyrA | unknown | — |
| Topoisomerase IV | parC|topB | inhibitor | — |
| DNA gyrase | gyrB|gyrA | inhibitor | — |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1991-12-31 | FDA | — | — |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
J01MA04 | ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › QUINOLONE ANTIBACTERIALS › Fluoroquinolones |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Enoxacin is on its molecule page.
| Molecular formula | C15H17FN4O3 |
|---|---|
| Molecular weight | 320.32 g/mol |
| CAS number | 74011-58-8 |
| InChIKey | IDYZIJYBMGIQMJ-UHFFFAOYSA-N |
| PubChem CID | 3229 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Enoxacin used for?
DrugCentral lists the following indications for Enoxacin: Acute gonococcal cervicitis, Acute gonococcal urethritis, Gonorrhea, Gonorrhea of pharynx, Gonorrhea of rectum and Urinary tract infectious disease.
How does Enoxacin work?
Its molecular targets in DrugCentral include TARBP2, ATP6V1B2, gyrA and parC|topB (inhibitor).
When was Enoxacin first approved?
Enoxacin was first approved by the FDA in 1991.
What is the chemical formula of Enoxacin?
Enoxacin has the molecular formula C15H17FN4O3 and a molecular weight of 320.32 g/mol.
Browse: all drugs starting with E · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 1013 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL826 — compound record and bioactivity
- PubChem CID 3229 — chemical identifiers
- DrugBank DB00467 — drug record
- FDA UNII 325OGW249P — substance identity
- DailyMed: FDA labels for Enoxacin — current prescribing information (label search)
- UniProt Q15633 (TARBP2) — target protein
- UniProt P21281 (ATP6V1B2) — target protein
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.